Tracers / [68Ga]Ga-BOT5035

[68Ga]Ga-BOT5035

Also written as [68Ga]Ga-BOT5035; [Ga-68]Ga-BOT5035
Radionuclide
Ga-68 t½ 67.71 min
Modality
PET
Production route
—
Stage
phase I
Syntheses indexed
1
Fibrosis (non-oncologic)Dosimetry and biodistribution studies

What it is

Compound class
bicyclic peptide
Target / mechanism
Platelet derived growth factor receptor β (PDGFR-β) PMID 32805638
Clinical application
Liver fibrosis PMID 32805638
Theranostic pair
—

Regulatory status

FDA
—
EMA (centralised)
—
Other approvals
—
Brand names
—

Clinical use

Typical injected activity
—
Uptake time
—

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
———43.7 ± 7.6%
no
97.7 ± 0.4%BOT503532805638
2020 Nucl Med Biol
synthesis platform (Modular-Lab PharmTrace, Eckert & Ziegler), disposable cassettes for 68Ga-labelling — The non-decay corrected radiochemical yield and radiochemical purity of the radiopharmaceutical were 43.7 ± 7.6% (n = 3, process validation)

Need this precursor?We can point you to suppliers for [68Ga]Ga-BOT5035, or handle the enquiry for you.

Get in touch

Quality control Preliminary — inferred from compound class

Ph. Eur. monograph
—
USP monograph
—
AppearancepHRCP HPLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrityMolar activityMetal impuritiesGe-68 breakthrough
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); Ga-68, generator production assumed (no synthesis data found) -> Ge-68 breakthrough (preliminary); receptor ligand with a saturable target -> molar activity (rule)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [68Ga]Ga-BOT5035.

Get in touch

Notes

Added from reverse module search (stage 6); 1 article(s) with Ga-68.